Forth Therapeutics

Forth Therapeutics develops precision medicines intended to target the cellular mechanisms driving organ fibrosis.

Its discovery platform combines single-cell and spatial genomics with patient-derived tissue data, including a large human liver disease dataset. These insights help identify disease-associated cells and potential targets for antifibrotic treatments.

A University of Edinburgh spinout with laboratory operations at Babraham Research Campus, the company is advancing early-stage programmes across fibrotic diseases.